Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer

Katchman et al.
Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer

Benjamin A Katchman1, I Tolgay Ocal2, Heather E Cunliffe3, Yu-Hui Chang4, Galen Hostetter3, Aprill Watanabe3, Janine LoBello3 and Douglas F Lake1*

Abstract

Introduction: Quiescin sulfhydryl oxidase 1 (QSOX1) oxidizes sulfhydryl groups to form disulfide bonds in proteins. Tumor specific expression of QSOX1 has been reported for numerous tumor types. In this study, we investigate QSOX1 as a marker of breast tumor progression and evaluate the role of QSOX1 as it relates to breast tumor growth and metastasis.

Methods: Correlation of QSOX1 expression with breast tumor grade, subtype and estrogen receptor (ER) status was gathered through informatic analysis using the “Gene expression based Outcome for Breast cancer Online” (GOBO) web-based tool. Expression of QSOX1 protein in breast tumors tissue microarray (TMA) and in a panel of breast cancer cell lines was used to confirm our informatics analysis. To investigate malignant cell mechanisms for which QSOX1 might play a key role, we suppressed QSOX1 protein expression using short hairpin (sh) RNA in ER+ Luminal A-like MCF7, ER+ Luminal B-like BT474 and ER- Basal-like BT549 breast cancer cell lines.

Results: GOBO analysis revealed high levels of QSOX1 RNA expression in ER+ subtypes of breast cancer. In addition, Kaplan Meyer analyses revealed QSOX1 RNA as a highly significant predictive marker for both relapse and poor overall survival in Luminal B tumors. We confirmed this finding by evaluation of QSOX1 protein expression in breast tumors and in a panel of breast cancer cell lines. Expression of QSOX1 in breast tumors correlates with increasing tumor grade and high Ki-67 expression. Suppression of QSOX1 protein slowed cell proliferation as well as dramatic inhibition of MCF7, BT474 and BT549 breast tumor cells from invading through Matrigel™ in a modified Boyden chamber assay. Inhibition of invasion could be rescued by the exogenous addition of recombinant QSOX1. Gelatin zymography indicated that QSOX1 plays an important role in the function of MMP-9, a key mediator of breast cancer invasive behavior.

Conclusions: Taken together, our results suggest that QSOX1 is a novel biomarker for risk of relapse and poor survival in Luminal B breast cancer, and has a pro-proliferative and pro-invasive role in malignant progression partly mediated through a decrease in MMP-9 functional activity.

Introduction

Breast adenocarcinoma is the most common cancer diagnosed in women throughout the world [1]. In 2012, an estimated 226,870 new cases of invasive breast cancer are expected to occur among US women, and an estimated 39,510 breast cancer deaths [2,3]. Despite significant advances in subtype classification of breast cancers, context-specific drivers of invasion and metastasis are still poorly understood. Our laboratory has focused on defining tumor-specific expression of proteins predicted to play an important role in malignant tumor biology. Recently our lab reported the identification of a short peptide that maps back to the C-terminus of QSOX1 in plasma from pancreatic cancer patients [4]. Subsequently,
we found that QSOX1 is over-expressed in tumor tissue from pancreatic cancer patients, but not adjacent normal tissue [5]. In vitro studies with pancreatic cancer cells determined that QSOX1 plays a significant role in pancreatic tumor cell growth and metastatic potential. To determine if QSOX1 overexpression may be functionally relevant in other tumor types we performed immunohistochemistry (IHC) on breast tissue microarrays and discovered that the expression of QSOX1 is specific to malignant breast tumors as well, and has diagnostic and prognostic significance in publicly available microarray datasets. These findings led us to hypothesize that over-expression of QSOX1 might be functionally conserved between pancreatic ductal adenocarcinoma and breast adenocarcinoma, prompting further exploration of the potential malignant function of QSOX1.

QSOX1 belongs to the family of FAD-dependent sulphydryl oxidases with expression in all sequenced eukaryotic organisms to date, indicating that QSOX1 provides a significant and highly conserved function among organisms. The primary enzymatic function of QSOX1 is oxidation of sulphydryl groups, generating disulfide bonds in proteins, ultimately reducing oxygen to hydrogen peroxide [6-8]. Previous work has reported the localization of QSOX1 to the Golgi apparatus and endoplasmic reticulum in human embryonic fibroblasts where it works independently as well as with protein disulfide isomerase to help fold nascent proteins in the cell [9-11].

In humans, QSOX1 is located on chromosome 1q24 and alternative splicing generates a long (QSOX1-L) and short (QSOX1-S) transcript [12]. Both, QSOX1-S and -L have identical functional domain organization, although QSOX1-L contains a predicted transmembrane domain that is not present in QSOX1-S due to alternative splicing in exon 12 [12]. While the majority of research to date has focused on the sulphydryl oxidase activity of QSOX1 to efficiently generate disulfide bonds in proteins [8,13,14], the major biological substrates of QSOX1 and the functional significance associated with each QSOX1 splice variant remain elusive.

Evidence supporting a pro-malignant role for QSOX1 expression has also been reported in prostate tumor cells by Song and colleagues [15]. Using knockdown studies they were able to show that the loss of NXX3.1, a transcription factor that is absent in 80% of metastatic prostate cancers, dramatically increased expression of QSOX1 in early stages of prostatic neoplasia and throughout the progression of invasive prostate cancer, but was not shown to be present in the normal prostate [15]. NXX3.1 is a known tumor suppressor that is exclusively expressed in luminal epithelial cells of the prostate. This finding is consistent with our observation of QSOX1 over-expression in the pancreas as well as in breast adenocarcinoma [5].

In the present study, we evaluated QSOX1 protein expression in breast adenocarcinoma cell lines MCF7, BT474 and BT549 and in a breast tumor tissue microarray. Using short hairpin RNA (shRNA) specific for QSOX1-S and -L, we assessed the effects of QSOX1 knockdown on cell growth, cell cycle, apoptosis, invasion and matrix metalloproteinase activity. The loss of QSOX1 significantly affected tumor cell proliferation and dramatically suppressed tumor cell invasion through Matrigel™. The addition of exogenous recombinant human QSOX1 (rhQSOX1) rescued the invasive capabilities of MCF7, BT474 and BT549 validating the pro-invasive function of QSOX1. We further report the mechanism of QSOX1-mediated invasion in vitro is due, in part, to elevated MMP-9 activity.

**Material and methods**

**Cell culture**

Breast adenocarcinoma MCF7, MDA-MB-468, MDA-MB-453, BT474, ZR75, BT549 and MDA-MB-231 cancer cell lines were cultured in DMEM with 10% fetal bovine serum (FBS) (Life Technologies, Grand Island, New York, USA). Immortal human non-tumorigenic breast epithelial cells (MCF10A) were cultured in Clontech KGM-2 keratinocyte media (Gibco). All cell lines were grown at 37°C with 5% CO₂.

All cell lines tested negative for mycoplasma contamination using the Venor GeM Mycoplasma Detection Kit, (Sigma-Aldrich, St. Louis, Missouri, USA).

**Immunohistochemistry (IHC) and scoring of staining intensity**

Breast tumor microarray slides were generated from 153 different breast cancer patients. Each patient’s tumor was represented in triplicate on the slides. Immunohistochemistry on breast tumor tissue microarray samples was performed exactly as previously described [16]. After staining the TMA slides with anti-QSOX1 rabbit polyclonal antibody, a board certified pathologist (ITO) scored the staining pattern as i) the percentage of cells with IHC staining for QSOX1 protein expression in the core tumor tissue sample (0: no staining, 1 (Low): 1 to 33%, 2 (Intermediate): 34 to 66%, 3 (High): 67 to 100%), and ii) the intensity of the antibody stain (0: no staining, 1: weak, 2: moderate, 3: strong staining intensity).

All samples were pre-existing and de-identified and, therefore, exempt from review by the human subjects Institutional Review Board at Arizona State University.

**Statistical assessment of QSOX1 IHC with molecular subtypes of breast cancer**

There were 153 patient tissue samples in triplicate stained with anti-QSOX1 rabbit polyclonal Ab (ProteinTech, Chicago, Illinois, USA). IHC staining was scored by a board certified pathologist (ITO). The amount and
intensity of QSOX1 staining/expression was scored on a scale of 0 to 3. The first IHC score number represents the percentage of cells staining (0: No staining, 1: to 33%, 2: 34 to 66%, 3: 67 to 100%), and the second represents intensity (0: No staining, 1: weak, 2: moderate, 3: strong staining intensity). We grouped the scores into four categories: 0 (No staining), 11/12/21 (Low staining), 22/13/31 (Intermediate staining) and 32/33/23 (High staining).

To evaluate the relationship between markers (Tumor grade, Her2, CK5/6, and Ki-67) and QSOX1, Pearson’s chi-square test was performed. Using two-sided P-values, statistical significance will be set at P ≤ 0.05.

Generation of short hairpin (sh) RNA and lentiviruses production

Two different shRNA for QSOX1 were obtained through DNASU in the lentiviral pLKO.1-puromycin selection vector. QSOX1 sh742, 5’-CCGGGCAAATGTGGTTGAGAAAATTTCTCGAGAAAACCTTTCTACACCACATTGCAATTGTTG - 3’ (sense), QSOX1 sh528, 5’-CCGGA-CAATGAGGAAGGCTTTT - 3’ (sense), and shScramble with target sequence 5’ -TCCGTGGTGAGCACTGGA-CAATGAGGAAGGCTTTT - 3’ (sense), and shScramble were produced as previously reported by Katchman et al. 2011 [5].

Generation of shQSOX1-transduced tumor cell lines

Stable transduction of sh742, sh528 and shScramble into MCF7, BT474 and BT549 cell lines was performed by first seeding the cells at 6 × 10⁵ cells/well in a six-well plate and incubating overnight. The next day the cells were transduced by adding 8 ug/mL polybrene (EMD Millipore Corporation, Billerica, Massachusetts, USA) and 200 ul sh742, sh528 and shScramble lentivirus produced from 293T cells to each well. The cells were then incubated for 24 hours. The following day, fresh DMEM with 10% FBS was added, containing 1 ug/mL puromycin (Sigma) to select for the transduced cells. QSOX1 knockdown was measured by Western blot.

SDS-PAGE-Western blotting

Western blotting was performed using cell lysates from MCF10A, MCF7, MDA-MB-468, MDA-MB-453, BT474, ZR 75, BT549 and MDA-MB-231. Cell lysates were harvested by harvesting 2.5 × 10⁶ cells by centrifugation followed by lysis using RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100) with 1x SigmaFAST Protease Inhibitor Cocktail Tablet, EDTA Free. Protein in the cell lysate was measured using the micro BCA protein assay kit (Thermo Fisher Scientific, West Palm Beach, Florida, USA). All samples were then normalized to 2 mg/mL (20 ug total protein per lane). Samples were run on 10% SDS-polyacrylamide gels then transferred onto Immuno-Blot™ PVDF Membranes (Bio-Rad, Hercules, California, USA). Rabbit polyclonal anti-QSOX1 (ProteinTech), rabbit polyclonal anti-alpha-tubulin (Sigma), mouse monoclonal caspase 3 (Cell Signaling Technology, Danvers, Massachusetts, USA), and rabbit polyclonal LC3 (Cell Signaling) antibodies were diluted according to the manufacturer’s instructions and as determined in preliminary experiments, in 1% BSA in 1x TBS + 0.01% Tween-20 and incubated overnight. Goat anti-rabbit or anti-mouse IgG-alkaline phosphatase or HRP secondary antibody was used at a 1:5,000 dilution and incubated with the blot for 1 h followed by washing. BCIP/NBT substrate (Pierce Chemical, Rockford, IL, USA) was added and the blot was developed at room temperature (RT) for approximately 10 minutes for alkaline phosphatase secondary antibody. For samples incubated in goat anti-rabbit or mouse HRP secondary antibody, the blots were developed using Novex ECL Chemiluminescent Substrate Reagent Kit (Novex Life Technologies, Grand Island, New York, USA). Quantification of band intensity was measured using Image J (Abramoff, M.D., Magalhaes, P.J., Ram, S.J. “Image Processing with ImageJ”. Biophotonics International, volume 11, issue 7, pp. 36-42, 2004) and is presented as percent change from the scrambled shRNA control. Full gel images are available in the Additional file 1. All gel images were annotated and processed using Adobe Photoshop CS3 (Adobe Systems Incorporated, San Jose, California, USA).

MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay

Cells were seeded at 3 × 10⁵ cells/well in a 96-well plate in triplicate and incubated at 37°C, 5% CO₂ over the course of five days. The MTT assay was performed over a five-day period according to the manufacturer’s instructions (Life Technologies Invitrogen-Molecular Probes, Vybrant MTT Cell Proliferation Assay Kit, Grand Island, New York, USA). Results are presented as mean +/- S.D. Student’s two tailed t-test was performed to determine significance.

Trypan Blue live/dead cell growth assay

Cells were seeded at 2.5 × 10⁴ cells/well in a 12-well plate in triplicate and incubated at 37°C, 5% CO₂ over the course of five days. The cells were removed with Cell Stripper, pelleted and brought back up in 1 mL PBS. A 30 ul aliquot was then used to determine total cell number. The cells were stained at a 1:1 ratio with 0.1% Trypan Blue and are reported as total number of live cells.
RNA Isolation and cDNA Synthesis

Total RNA isolation was performed according to the manufacturer’s instructions for animal cells using spin technology (RNase Mini Kit, Qiagen, Gaithersburg, Maryland, USA). After RNA was isolated from each sample was reverse transcribed with qScript cDNA Synthesis Kit (Quanta Biosciences, Gaithersburg, Maryland, USA) according to the manufacturer’s instructions.

Quantitative Real Time PCR (qPCR)

The relative level of GAPDH, QSOX1-L, QSOX1-S, MMP-2 and MMP-9 were analyzed in each sample by qPCR. Each cDNA sample was normalized to 100 ng/µl in molecular grade water along with 100 nM final concentration of each primer and 1× final concentration of PerfeCta SYBR Green Fast Mix (Quanta Biosciences, Gaithersburg, Maryland, USA), ROX to a final volume of 10 µl. qPCR was performed using PerfeCta SYBR Green FastMix, ROX from Quanta Biosciences (Quanta Biosciences, Gaithersburg, Maryland, USA) on an ABI7900HT thermocycler, Applied Biosystems Inc. (Life Technologies, Grand Island, New York, USA). Reaction protocol: initial denaturation was as follows - 95°C for 3 minutes; PCR Cycling (40 cycles) 1.) 95°C, 30 sec. 2.) 55°C, 30 sec. 3.) 72°C, 1 minute; Melt Curve (Disso- ciation stage). The primer sequences for the genes ana- lyzed are: GAPDH Forward 5'- GGCCCTCAAAGG AGTAAGACC; GAPDH Reverse 5' - AGGGGTCTACA TGGCAGCTG; QSOX1-S Forward 5' - TGGCTTAGCC ACAACAGGGTCAAT; QSOX1-S Reverse 5' - TGTG CAGGCGAGACAAATTCAC; QSOX1-L Forward 5' - TTGGCTCCTTGTCTGGAAGT; QSOX1-L Reverse 5'-TGGTGCAGGAGCTCTTCTGTCTC; MMP-2 Forward 5' - TTGACGGTAAAGGACGAGCATC; MMP-2 Reverse 5' - ACTTGCAGTACTCCCATCG; MMP-9 Forward 5' - TTGACACGGCAAGAATGTT; MMP-9 Reverse 5' - CCCTCAGTGAGGCC GTACAT. Each reaction was performed in triplicate with the data representing the averages of one experiment.

In the shRNA experiment, expression of MMPs was normalized to the non-targeted GAPDH to determine ΔCq. ΔCq replicates were then exponentially transformed to the ΔCq expression after which they were averaged ± standard deviation. The average was then normalized to the expression of the shScramble control to obtain the ΔΔCq expression. Significance was determined using the Student’s two-tailed t-test. Results presented are from one of three independent experiments.

Gelatin zymography

The identification of MMP was performed using gelatin zymography. Zymography experiments were performed essentially as previously described by Katchman et al. [5]. Minor changes in the protocol are the inclusion of untreated MCF7 and BT549 cells as well as short hairpin-transduced cells were seeded at 5 x 10^5 cells/well (12-well plates) in DMEM with 10% FBS. The next day, cells were then washed with 1 x PBS and the media was changed to serum-free DMEM and incubated for 48 hours instead of 24 hours before being collected and protein concentrations determined using a BCA assay. Quantification of band intensity was measured using Image J and is presented as the percent change from the scrambled shRNA control.

Results

Expression of QSOX1 correlates with poor prognosis in patients with Luminal B breast cancer

Bioinformatic analysis of QSOX1 transcript expression was assessed using data from the Gene expression based Outcome for Breast cancer Online algorithm (GOBO) [17]. GOBO is a web based analysis tool that utilizes Affymetrix gene expression data curated from 1,881 breast cancer patients with associated stage, grade, nodal status and intrinsic molecular classification based on the paradigm first reported by the Perou Laboratory [18]. Expression of QSOX1 was significantly higher in ER+ tumors compared to ER- (P-value < 0.00001), with the highest expression observed in Luminal A, Luminal B and Normal-like subtypes (Figure 1a, b). The lowest QSOX1 transcript expression was observed in HER2- enriched and basal tumors. Using the GOBO tool, we
performed a series of Kaplan Meier analyses to determine whether QSOX1 expression is associated with relapse free survival (RFS) and overall survival (OS) (Figure 1c, d and Additional file 2). While elevated QSOX1 expression is not associated with survival when considering all breast tumor subtypes together (see Additional file 2), it is highly associated with poor RFS ($P = 0.00062$) and OS ($P = 0.00031$) in Luminal B tumors (Figure 1c, d). The expression of QSOX1 correlates with increasing tumor grade as well as poor overall survival in patients diagnosed with grade 2 ($P = 0.04242$) and grade 3 ($P = 0.07095$) breast tumors (see Additional file 2i-k). Elevated QSOX1 was also associated with reduced OS in luminal A tumors (see Additional file 2g, h) and is a predictor of poor OS for patients who did not receive systemic treatment (see Additional file 2d).

**Evaluation of QSOX1 expression by immunohistochemistry**

Results from the GOBO transcript expression analysis fueled investigation of QSOX1 at the protein level in breast tumors. A breast tumor tissue microarray composed of breast tumors from over 150 different patients was stained with a rabbit anti-QSOX1 polyclonal antibody and scored by a board certified pathologist (ITO). Figure 2b shows no expression of QSOX1 in normal breast tissue. Figure 2c-f
represent a pattern of increasing $QSOX1$ expression observed in the TMA in grade 1, grade 2 and grade 3 invasive ductal carcinomas and a grade 3 invasive lobular carcinoma. Statistical evaluation of $QSOX1$ expression by immunohistochemistry (IHC) demonstrated an association with ER+ tumors, and a strong association with high Ki-67 expression in patients with a high $QSOX1$ IHC score (Figure 2a, Table 1). There was no relationship observed for $QSOX1$ expression in HER2+ tumors or cytokeratin markers (CK 5/6) positive tumors. These data are consistent with the correlation observed in the GOBO data.

Interestingly, higher grade tumors were associated with a higher $QSOX1$ IHC score (Figure 2a, Table 1). Conversely, lower $QSOX1$ protein expression is significantly associated with lower grade tumors. This is consistent with an association between $QSOX1$ expression and more aggressive ER+ tumors.

Evaluation of $QSOX1$ expression by Western blot

$QSOX1$ expression in human breast adenocarcinoma was assessed in six different breast tumor cell lines, and a transformed non-tumorigenic breast cell line, MCF10A [19,20]. Similar to our previous studies in pancreas cancer [5], the short form of $QSOX1$ is expressed as the predominant splice variant in each cell line examined (Figure 3a). Consistent with the GOBO and IHC expression data, we found that the expression of $QSOX1$-S protein was more highly expressed in luminal-like cell lines MCF7 (ER+), MDA-MB-453 (ER-), ZR 75 (ER+) and BT474 (ER+) compared to basal-like BT549 and MDA-MB-231 cell lines. Interestingly, $QSOX1$ was most weakly expressed in transformed normal MCF10A cells which do not form tumors in immunodeficient animals.

Expression of $QSOX1$ in tumor cells promotes cellular proliferation

To begin to assess the mechanistic role that $QSOX1$ plays in tumor cells we stably knocked-down $QSOX1$ expression in MCF7, BT549 and BT474 cells using two lentiviral shRNA constructs, sh742 and sh528 (Figure 3b-d). $QSOX1$ protein expression was assessed following stable knockdown relative to isogenic parental cell lines by Western
blotting. Densitometry of the QSOX1 protein relative to alpha-tubulin expression indicates that sh742 and sh528 resulted in a knock-down of QSOX1-S expression in MCF7 cells by 85% and 82%, respectively. In BT549 cells the knock-down was 65% and 77%, and for BT474 cells by 40% and 36%, respectively (Figure 3b-d).

The growth rates of shQSOX1-transduced MCF7, BT549 and BT474 cells were then evaluated compared to isogenic controls (Figure 3e-j). An equal number of untransduced (parental), shScramble, sh742 and sh528 cells were seeded in 96-well plates and assayed for proliferation over five days using the MTT assay. ShQSOX1-transduced MCF7, BT549 and BT474 cells displayed a decrease in cell growth compared to shScrambled and parental controls (Figure 3e-g). In MCF7 cells, sh742 and sh528 showed a 66% decrease in cell growth, while sh742 and sh528 suppressed growth of BT549 by 78% and 69%, respectively, and sh742 and sh528 suppressed growth of BT474 by 52% and 29%, respectively by Day 5. We confirmed our MTT results by performing Trypan Blue staining over five days (Figure 3h-j) using the same incubation conditions as in the MTT assay. These results suggest that QSOX1 helps drive tumor cell growth.

**Cell cycle, apoptosis and autophagy analysis**

In non-tumor fibroblasts, expression of QSOX1 was correlated with the quiescent stage, G0, of the cell cycle and overexpression of QSOX1 was shown to protect MCF7 cells for ROS mediated apoptosis [21], this led us to hypothesize that a shQSOX1-mediated decrease in cell proliferation could be the result of abnormal regulation of the cell cycle, an increase in apoptosis or the result of autophagosome formation. To address this, propidium iodide (PI) was used in flow cytometry to evaluate the effects of shQSOX1 on cell cycle. In MCF7 cells, both shQSOX1 RNAs showed a slight decrease in G1 and an increase (11 to 12%) in S phase, while in BT474 cells both shQSOX1 RNAs showed a slight 12% increase in G1 and a 26% decrease in S phase but neither shQSOX1 RNA sequence had any effect in BT549 cells compared to untreated and shScramble controls (see Additional file 3a-c).

---

**Table 1 Statistical assessment of QSOX1 protein expression with molecular subtypes of breast cancer**

| IHC Score               | No QSOX1 staining (% | Low QSOX1 staining (% | Intermediate QSOX1 staining (% | High QSOX1 staining (%) | P-value |
|-------------------------|----------------------|-----------------------|---------------------------------|--------------------------|---------|
| Grade                   | (n = 17)             | (n = 47)              | (n = 24)                        | (n = 65)                 |         |
| 1                       | 53.3                 | 42.2                  | 25                              | 10.8                     | *0.0003 |
| 2                       | 33.3                 | 33.3                  | 41.7                            | 32.3                     |         |
| 3                       | 13.3                 | 24.4                  | 33.3                            | 56.9                     |         |
| ER                      | 80                   | 89.1                  | 73.9                            | 55.4                     | *0.0013 |
| ER -                    | 20                   | 10.9                  | 26.1                            | 44.6                     |         |
| HER2                    | 11.8                 | 6.4                   | 29.2                            | 14.1                     | 0.0811  |
| HER2 -                  | 88.2                 | 93.6                  | 70.8                            | 85.9                     |         |
| CKS/6                   | 100                  | 95.7                  | 87.5                            | 83.1                     | 0.0733  |
| CKS/6 -                 | 0                    | 4.3                   | 12.5                            | 17                       |         |
| CKS/6 +                 |                       |                       |                                 |                          |         |
| KI-67                   | 33.3                 | 33.3                  | 41.1                            | 18.5                     | *0.0011 |
| Low                     | 44.4                 | 45.5                  | 17.7                            | 16.7                     |         |
| Intermediate            | 22.3                 | 21.2                  | 41.2                            | 64.8                     |         |
| High                    | 86.7                 | 91.3                  | 91.3                            | 64.1                     | *0.0016 |
| ER & HER2               | 13.3                 | 8.7                   | 8.7                             | 35.9                     |         |
| ER- HER2 -              | 86.7                 | 91.3                  | 91.3                            | 64.1                     |         |
| Others                  | 100                  | 95.7                  | 95.8                            | 84.6                     | 0.0923  |
| ER, HER2 and CKS/6      | 0                    | 4.3                   | 4.2                             | 15.4                     |         |
| ER, HER2, CKS/6: 1/2/3  | 100                  | 95.7                  | 95.8                            | 84.6                     |         |
| Others                  |                       |                       |                                 |                          |         |

QSOX1 expression was grouped into four categories based on the percentage of cells stained and the intensity of QSOX1 expression: No expression, Low QSOX1 expression, Moderate QSOX1 expression and Strong QSOX1 expression (see material and methods for detailed explanation). Each number represents the percentage of QSOX1 positive or negative cells within each molecular subtype of breast cancer (n = total number of tissue samples within each category). Pearson’s chi-square test was performed to determine a relationship between the molecular subtypes and QSOX1 expression. Statistical significance using a two-sided P-value was set at P ≤ 0.05*.
Next we determined if the decrease in cellular proliferation was due to an increase in apoptosis or autophagy (see Additional file 3d, e). To assess apoptosis, we analyzed MCF7 and BT474 transduced cells for Annexin V/PI [22]. We subsequently probed MCF7 and BT549 transduced cells for LC3, a protein that is necessary for autophagosome formation [23]. If the expression of QSOX1 prevented cellular apoptosis or autophagy we would expect to see an increase in expression of Annexin V and LC3 in shQSOX1 transduced cells, but we did not observe any statistically significant increases in Annexin V positive cells (see Additional file 3d-f). This correlates with our previous results in pancreas cancer that the suppression of QSOX1 does not lead to cell death or autophagy.

**Suppression of QSOX1 expression inhibits tumor cell invasion**

The process of tumor cell invasion involves the degradation of basement membrane (BM) components such as laminin, collagen and fibronectin before a tumor cell is
able to invade other tissues [24]. We performed a modified Boyden chamber assay using Matrigel™-coated inserts in which tumor cells must degrade the Matrigel™ and migrate through a membrane with 8 um pores to gain access to nutrient rich media. Sh742 and sh528-transduced MCF-7, BT549 and BT474 tumor cells were added to Matrigel-coated, 8 um pore inserts in serum-free medium. After 72 (MCF7) and 48 (BT549 and BT474) hours of incubation, tumor cells that were able to degrade Matrigel™ and migrate through 8 um pores onto the underside of the insert were counted (Figure 4a-c). Our results demonstrate that knockdown of QSOX1 expression in MCF7 leads to a 65% and 71% reduction in invasion of sh742 and sh528 transduced tumor cells, respectively. For BT549 sh742 and sh528 - transduced tumor cells, 60% and 40% decreases in invasion through Matrigel™ were observed. Suppression of QSOX1 expression in BT474 cells leads to an 85% reduction in invasion of both sh742 and sh528 transduced tumor cells. These data suggest that QSOX1 plays a role in regulating invasive behavior in vitro irrespective of breast tumor subtype and hormone receptor status.

To prove that suppression of QSOX1 protein expression was responsible for loss of tumor cell invasion, we performed a rescue experiment in which recombinant human QSOX1 (rhQSOX1, generously provided by Dr. Colin Thorpe) was added to shQSOX1-MCF7, shQSOX1-BT549 and shQSOX1-BT474 cells during the invasion assay. As a control for the enzymatically active QSOX1, a mutant rhQSOX1 in which the CxxC motif in the thredoxin-1 domain was mutated to AxxA (rhQSOX1(AA), generously provided by Dr. Debbie Fass) was added to the invasion assay. Addition of enzymatically active rhQSOX1 rescued the invasive phenotype of the shQSOX1-transduced tumor cells (Figure 4d-f), while the addition of the rhQSOX1(AA) did not rescue invasion of the shQSOX1-transduced tumor cells.

**Decrease in QSOX1 leads to a decrease in matrix metalloproteinase activity**

Since knockdown of QSOX1 resulted in decreased breast tumor cell invasion, it was important to determine a mechanism for how QSOX1 might facilitate invasion. Matrix metalloproteinases (MMP) have been shown to play key roles in breast tumor invasion and metastasis [24]. Both MMP-2 and -9 mRNA and protein levels have been shown to contribute to breast tumor invasion, metastasis and angiogenesis [25]. Since previous work demonstrated that QSOX1-S is secreted into the extracellular matrix where MMPs are activated, we hypothesized that QSOX1 might help activate MMP-2 and -9 proteins. MCF7 and BT549 cells transduced with shScramble, sh742 and sh528 were plated at equal densities and allowed to incubate in serum free media for 48 hours, after which the supernatants were collected and analyzed by gelatin zymography to determine if the loss of QSOX1 leads to a decrease in the functional activity of MMP-2 and -9.

Initial analysis of the results indicates that MCF7 and BT549 possess similar MMP profiles even though it is known that BT549 cells are more invasive. Luminal B-like breast tumor cell lines BT474 and ZR75 do not secrete detectable levels of MMPs [25,26]. However, both MCF7 and BT549 supernatants contain MMP-9 homodimer (130 kDa), a large amount of proteolytically active pro-MMP-9 (92 kDa) with lesser concentrations of proteolytically active pro-MMP-2 (72 kDa).

We found that supernatants from MCF7 cells transduced with sh742 and sh528 showed a 70% and 77% decrease, respectively, in pro-MMP9 activity compared to shScramble (Figure 5a). MCF7 supernatants from cells transduced with sh742 and sh528 also showed a 50% and 60% decrease in active MMP-9 (a-MMP-9) as well (Figure 5a). Supernatants from BT549 cells transduced with sh742 and sh528 showed a 34% and 88% decrease, respectively, in MMP-9 (Figure 5b). Decreases in the proteolytic activity of MMP-9, using gelatin as a substrate, provide a mechanism for the shQSOX1-mediated suppression of invasion through Matrigel™.

To extend our hypothesis that QSOX1 is activating or modifying MMPs post-translationally, we performed a Western blot on total cell lysate from MCF7 and BT549 transduced cells as well as performed quantitative real time PCR (qPCR) to determine if the loss of QSOX1 affected MMP protein and RNA levels (Figure 5c, d). Our results indicate that the intracellular amount of MMP-2 and -9 protein is similar between the untreated, shScramble, sh742 and sh528 samples in MCF7 and BT549 cells (Figure 5c). Figure 5d demonstrates that the loss of QSOX1 also has no significant effect on the transcriptional activity of MMP-2 and -9. These results add confidence to our hypothesis that QSOX1 is involved in the post-translation activation of MMPs.

**Discussion**

QSOX1 protein was reported by our laboratory to be over-expressed in tumors from patients diagnosed with pancreatic ductal adenocarcinoma (PDA) [4]. In a subsequent study we reported that expression of QSOX1 promotes pancreatic tumor cell growth and invasion [5]. To determine if QSOX1 was also over-expressed in breast cancer, a GOBO analysis was performed using data from over 1,800 breast cancer cases. A prominent finding in this analysis is that the highest levels of QSOX1 expression in Luminal B breast cancer correlate with very poor RFS and OS (Figure 1c, d; Additional file 2e, f). The median survival in patients with Luminal B breast cancer who over-express QSOX1 is approximately four years.
Figure 4 QSOX1 promotes tumor cell invasion. a.) MCF7, b.) BT549 and c.) BT474 cells transduced with shScramble, sh742 and sh528 shRNAs were seeded at equal densities in the top chamber of Matrigel™ invasion wells and allowed to incubate for 48 (BT549 and BT474) and 72 (MCF7) hours, after which cells that had digested Matrigel™ and migrated through the 8 um pores were counted on the underside of the insert. Representative 20x images are presented. MCF7 cells transduced with sh742 and sh528 show a 65% and 71% decrease in invasion. BT549 cells transduced with sh742 and sh528 showed a 60% and 40% decrease in invasion. BT474 cells transduced with sh742 and sh528 show an 82% decrease in invasion. Each knockdown was compared to shScramble controls. The invasive phenotype of shQSOX-transduced MCF7 (d.), BT549 (e.) and BT474 (f.) cells was rescued by exogenous incubation with catalytically active rhQSOX1. rhQSOX1 (AA) mutant is a mutant without enzymatic activity, generously provided by Dr. Debbie Fass. Graphs represent average ± SD (MCF7, BT549 and BT474 n = 3), significance *, P < 0.05, ** P < 0.005.
The prognostic power of QSOX1 expression for RFS and OS increases when Luminal B breast cancer cases are divided into quintiles using the GOBO analysis tool for which patients with the highest fifth expression of QSOX1 have RFS of less than two years and OS of less than three years (see Additional file 2e, f). In support of our GOBO analysis, showing that expression of QSOX1 is an indicator of poor OS and RFS in Luminal B breast cancer patients, we performed IHC on breast TMA samples. We were able to confirm that expression of QSOX1 significantly correlates with ER+ breast tumor (P = 0.0013) cells as well as correlating with high Ki-67 expression (P = 0.0011), further supporting a role for QSOX1 in cellular proliferation (Figure 2a). Additionally, over-expression of QSOX1 mRNA in the GOBO analysis and high levels of protein in IHC correlate with increasing tumor grade in our breast tumor TMA analyses (Figure 2; Table 1; Additional file 2i-k). Expression of QSOX1 did not correlate with survival in HER2 enriched tumors, ER- tumors or in tumors subtyped as basal-like. Importantly, in patients who did not receive systemic therapy (presumably due to diagnosis of very early stage disease), QSOX1 appears to be a predictor of poor OS (see Additional file 2d). However, this association was not strong until more than five years post diagnosis. These data collectively suggest that QSOX1 is associated with highly proliferative ER+ tumors and warrants further preclinical and prospective validation as a diagnostic and prognostic biomarker in ER+ tumors.

Tumor cells in which QSOX1 expression was suppressed using shRNAs grew at less than half the rate of shScramble and untreated controls in MCF7, BT549 and BT474 cells (Figure 3e-j). The results of the MTT and Trypan Blue assays confirm our breast TMA findings.

**Figure 5** Reduced expression of QSOX1 in MCF7 and BT549 cells leads to a decrease in functional MMP-9 activity. Gelatin zymography of a) MCF7 and b) BT549 conditioned media shows a decrease in MMP-9 homodimers (130 kDa) and MMP-9 (92 kDa). The percent decrease in MMP-9 expression in MCF7 was: sh742: 70% (P = 0.0171); sh528: 77% (P = 0.0182), and in BT549 was: sh742: 34% (P = 0.0531); sh528: 88% (P = 0.00564) compared to shScramble control. c) Western blots of total cell lysate from shRNA treated MCF7 and BT549 probing for MMP-2 and -9 show insignificant changes compared to shScramble control. Full images can be seen in Additional file 1. d) QPCR of QSOX1 transcripts and MMP-2 and -9 transcripts. The graph represents relative gene expression calculated as \( \Delta \Delta C_q \) using GAPDH as the endogenous reference gene. MMP-2 - MCF7 sh742 (P = 0.5294), sh528 (P = 0.2112); BT549 sh742 (P = 0.0054), sh528 (P = 0.0019). MMP-9 - MCF7 sh742 (P = 0.3981), sh528 (P = 0.3385); BT549 sh742 (P = 0.4192), sh528 (P = 0.0701). Average ± SD; significance was determined using a Student’s two-tailed t-test.
showing that high expression of QSOX1 correlates with high Ki-67 expression. Our attempt to explain the decrease in cell growth by abnormal cell cycle regulation, apoptosis and autophagy suggests that QSOX1 is not involved in apoptosis, or autophagy (see Additional file 3d-f), but may marginally affect cell cycle, as we observed a stall in G1 and an increase in S phase in MCF7 cells (luminal-like) and an insignificant increase in G1 and a decrease in S phase in BT474 (luminal-like) cells compared to shScramble controls (Additional file 3a-c). However, there were no observable changes in BT549 cells (basal-like). These results, combined with our findings in PDA suggest that QSOX1 is unlikely to play a significant role in cell cycle. Our analysis of apoptosis and autophagy as a second possible mechanism contributing to the observed decrease in cell growth did not reveal significant increases in Annexin V/PI or LC3 expression (autophagy) in our shRNA treated cells (see Additional file 3d-f). We also did not observe any increases in Trypan Blue positive cells during our cell growth assays compared to our shScramble control (data not shown). At this time, the exact function of QSOX1 with respect to tumor cell proliferation remains elusive.

The ability of a tumor cell to invade is one of several hallmarks of cancer [27]. Based on our previous results showing that QSOX1 over-expression in pancreas tumor cells contributes to invasion, we hypothesized that the over-expression of QSOX1 in breast adenocarcinoma would elicit a similar phenotype. MCF7, BT549 and BT474 cells transduced with QSOX1 shRNAs exhibited significant decreases in their ability to degrade basement membrane components and invade through Matrigel™ (Figure 4a-c). MCF7 cells are a poorly invasive, luminal-A like breast cancer cell line, while BT549 (basal-like) and BT474 (Luminal-B like) cells are highly invasive [28,29]. Although the invasive capabilities are dramatically different between these cell lines, QSOX1 knockdown suppressed growth and invasion in all cell lines irrespective of the level of QSOX1 expression (Figure 4a) and molecular tumor subtype. Addition of exogenous recombinant QSOX1 protein to shQSOX1 transduced tumor cells rescued their invasive properties (Figure 4d-f), confirming previous data suggesting that QSOX1 is secreted into the extracellular matrix.

These findings indicate the advantage that QSOX1 provides to breast and pancreas tumors may be highly conserved and universal among other tumor types. However, one cannot draw this definitive conclusion from the phenotypic behavior of cells cultured in 2D [30,31]. What we can conclude from our human TMA analysis of QSOX1 protein expression is that QSOX1 is a very specific marker of tumor cells and that the expression of QSOX1 correlates with increased proliferation (high Ki-67) and an increase in tumor grade consistent with the characteristics of highly invasive tumors. QSOX1 is likely to become functionally relevant when considered not only in specific molecular subcontext (such as ER+ tumor cells), but in specific environmental contexts within the 3D breast tumor microenvironment with the full complement and complex interplay of autocrine and paracrine signaling components known to be important in tumor progression [28,30,32,33].

MMPs are a family of proteases that are involved in the degradation of basement membrane components contributing to tumor cell invasion and proliferation [34]. In breast tumors, gelatinases, MMP-2 and MMP-9 have been shown to play a significant role in growth and metastasis, as their expression is correlated with aggressive forms of breast cancer [25,34,35]. Gelatinases are secreted into the extracellular matrix in their inactive, pro-form where they can be activated through either a cysteine switch or shift in the prodomain mediated by integrins and laminin in basement membranes and structural proteins, such as vimentin [25]. Thiol binding proteins, such as glutathione, have also been shown to help fold and activate MMPs [35]. Our data suggest that MMPs could be one substrate of QSOX1. To address this we performed gelatin zymography to assess functional activity MMPs. Our data reveal that knockdown of QSOX1 protein expression in both MCF7 and BT549 cells leads to a decrease in MMP-9 functional activity compared to shScramble control (Figure 5a, b). While the functional activity of MMP-2 and -9 was suppressed, mRNA encoding MMP-2 and -9 remained relatively constant in MCF-7 cells and increased in BT549 cells (Figure 5c, d). BT474 cells unfortunately do not express or secrete levels of MMP-2 and -9 detectable by gelatin zymography [25,36]. Interestingly, when we knock down QSOX1 in BT474 cells we observe the same phenotypic effects indicating that there are multiple substrates of QSOX1 contributing to our observed decrease in cellular proliferation and invasion. Taken together, the data suggest that QSOX1 may post-translationally activate MMPs, although this requires further study to be a definitive conclusion. Future proteomic analysis may reveal a wide spectrum of substrates linked to cellular proliferation, basement membrane production and cellular motility connecting the phenotypes observed in this report to QSOX1 expression.

QSOX1 is expressed during embryonic development in mouse and rat during key migratory stages [37]. This developmental data combined with our results indicating that QSOX1 expression facilitates degradation of basement membranes suggests that tumor cells over-express QSOX1 to allow them to break down basement membranes and invade into adjacent tissues or into circulation. It will be interesting to assess QSOX1 expression in circulating tumor cells. QSOX1 expression in Luminal B
subtype may help further stratify which tumors are likely to be more aggressive, leading to poor overall survival. Notably from these data we can project that targeting QSOX1 irrespective of tumor subtype could help to slow tumor cell proliferation as well as tumor cell invasion. This finding provides another tool for physicians and their patients to decide whether to more aggressively treat patients with Luminal B breast cancer whose tumors express high levels of QSOX1.

While this paper was under review and revision, Pernodet et al. reported that QSOX1 over-expression in breast cancer is associated with a good prognosis. This report creates a discrepancy of the function of QSOX1 in breast cancer. We previously published that QSOX1 promotes pancreatic cancer growth and invasion in a manner very similar to the results shown here. We became interested in the role of QSOX1 in breast cancer after we employed the publicly available GOBO analysis tool to evaluate QSOX1 gene expression among 1,881 cases of molecularly subtyped breast cancer. The GOBO analysis clearly indicates that QSOX1 expression predicts a poor prognosis in patients with luminal type and normal-like breast cancer. This initial GOBO analysis fueled our investigation of QSOX1 in breast cancer. Unlike the 217 patient dataset used by Pernodet et al., GOBO analysis is completely independent, and agrees with our findings that QSOX1 is a bad actor in breast cancer. Furthermore, we have shown immunohistochemically that higher grade tumors express more QSOX1 protein than lower grade tumors. It will be interesting to determine the true role of QSOX1 in breast and other cancers.

Conclusions
In this study we show for the first time that QSOX1 over-expression is associated with features of poor prognosis in patients whose tumors highly express QSOX1 and that QSOX1 promotes breast tumor growth and invasion in vitro, perhaps mediated mechanistically by post-translational activation of MMP-9 functional activity. While further research is still needed to understand the role of QSOX1 in vivo, the results presented here strongly suggest that targeted inhibition of QSOX1 may stall cancer progression.

Additional material

Additional file 1: Full Western blot and gelatin zymography images. a) Western blot of MCF10A confluent, MCF10A 30% confluent, MCF7, MDA-MB-468, MDA-MB-543, BT549 and MDA-MB-231 total cell lysate probing for QSOX1 and Baxin. b) Western blot of MCF7 Untreated, shScramble, sh742, sh528 and sh616 total cell lysate probing for QSOX1. c) Western blot of MCF7 Untreated, shScramble, sh742 and sh616 total cell lysate probing for QSOX1. d) Western blot of MCF7 Untreated, shScramble, sh742, sh528 and sh616 total cell lysate probing for QSOX1. e) Western blot of MCF7 Untreated, shScramble, sh742, sh528 and sh616 total cell lysate probing for QSOX1. f) Western blot of MCF7 Untreated, shScramble, sh742, sh528 and sh616 total cell lysate probing for alpha-tubulin. g) Western blot from left to right MCF7 untreated, shScramble, sh742, sh528 and sh616, H2O2 treated MCF7 cells, probing for alpha-tubulin. h) Western blot of MCF7 Untreated, shScramble, sh742, sh528 and sh616, H2O2 treated MCF7 cells, probing for Vimentin. i) Western blot from left to right MCF7 untreated, shScramble, sh742, sh528 and sh616, H2O2 treated MCF7 cells, probing for LC3. j) Western blot of BT549 untreated, shScramble, sh742, sh528 and sh616 probing for Vimentin. k) Western blot of BT549 untreated, shScramble, sh742, sh528, sh616 and sh613 probing for alpha-tubulin. l) Western blot from left to right MCF7 untreated, shScramble, sh742, sh528 and sh616, H2O2 treated MCF7 cells, probing for caspase 3. m) Gelatin zymography of BT549 untreated, shScramble, sh742, sh528 and sh616. Clear bands indicated MMP-2 and -9 digestion. n) Western blot of, from left to right, MCF7 untreated, shScramble, sh742 and sh528, BT549 untreated, shScramble, sh742 and sh528. Blot was probed for MMP-2, then stripped and reprobed for MMP-9. o) Western blot of ZR75, BT474 and MCF7 Untreated, shScramble, sh742 and sh528 probing for QSOX1. p) Western blot of BT474 untreated, shScramble, sh742 and sh528 probing for QSOX1 and alpha-tubulin.

Additional file 2: GOBO (Gene expression based outcome for breast cancer online) analyses of QSOX1 gene expression. For a-d and g-k, gray line represents tumors weakly expressing QSOX1 transcript; red line represents tumors strongly expressing QSOX1 transcript. Kaplan-Meier analysis using relapse free survival (RFS) and overall survival (OS) as an endpoint for a) All Tumors - RFS (n = 914); b) All Tumors - OS (n = 737). c) Untreated Tumors - RFS (n = 415); d) Untreated Tumors - OS (n = 307); e) Luminal B - RFS (n = 130); f) Luminal B - OS (n = 98); g) Luminal A - RFS (n = 261); h) Luminal A - OS (n = 189); i) Grade 1 - OS (n = 139); j) Grade 2 - OS (n = 315); k) Grade 3 - OS (n = 262).

Additional file 3: Suppression of QSOX1 in MCF7 and BT549 cells does not lead to a significant increase in apoptosis or autophagy a) MCF7, b) BT549 and c) BT474 cells transfected with shRNAs were analyzed for deviations in the cell cycle. Analysis was performed using propidium iodide to label DNA and analyze cells in G1, S and G2/M of the cell cycle by flow cytometry. Annexin V/Propidium iodide analysis was performed on d) MCF7 and e) BT474 cells to assess apoptosis. Western blot analysis of a) MCF7 and BT549 untreated, shScramble, sh742 and sh528 total cellular protein probed for LC3. BT549 cells incubated exogenously with 50 μM H2O2 to induce expression of LC3 (autophagy) is used as a positive control. Full gel images can be seen in Additional file 1.

Abbreviations
BM: Basement membrane; BSA: Bovine serum albumin; DMEM: Dulbecco’s modified Eagle’s medium; ER: Estrogen receptor; FBS: Fetal bovine serum; GOBO: Gene Expression Based Outcome for Breast Cancer Online; IDC: Invasive ductal carcinoma; IHC: Immunohistochemistry; ILC: Invasive lobular carcinoma; MMP: Matrix metalloproteinases; MITT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; a yellow tetrazole; OS: Overall survival; PDA: Pancreatic ductal adenocarcinoma; PET: Polyethylen terephthalate; PI: Propidium iodide; qPCR: Quantitative real time PCR; QSOX1: Quiescin sulfhydryl oxidase 1; RFS: Relapse free survival; rhQSOX1: Catalytically active recombinant human QSOX1; qSOX1: Catalytically inactive mutant; shRNA: short hairpin RNA; TMA: Tumor tissue microarray.

Authors’ contributions
BAK participated in the design, execution, analysis and interpretation of in vitro studies and drafting of the manuscript. ITO provided pathological interpretation of IHC results, statistical analysis and contributed to the drafting of the manuscript. HEC participated in analysis and interpretation of results and provided significant input into drafting the manuscript. YHC provided statistical evaluation of IHC results and contributed to the drafting of the manuscript. GH participated in the design and interpretation of in vitro results. AW and JL performed IHC on TMA samples. DL participated in
the conception, design, interpretation of results and drafting of the manuscript. All authors have read and approved the manuscript for publication.

Competing interests

The authors declare that they have no competing interests.

Author details

1School of Life Sciences, Arizona State University, PO Box 874501, Tempe, AZ 85287-4501, USA. 2Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 E. Shea Blvd, Scottsdale, AZ 85259, USA. 3Department of Investigational Pathology, Translational Genomics Research Institute, 445 N Fifth St, Phoenix, AZ 85004, USA. 4Division of Health Sciences Research, Mayo Clinic Arizona, 13208 E. Shea Blvd, Scottsdale, AZ 85259, USA.

Received: 13 June 2012 Revised: 13 February 2013 Accepted: 14 March 2013 Published: 28 March 2013

References

1. Sgroi DC. Preinvasive breast cancer, Annu Rev Pathol 2010, 5:193-221.
2. Cancer Facts and Figures American Cancer Society. 2012 [http://www.cancerresearch.org/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012]
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
4. Antwi K, Hostetter G, Demere M, Decker G, Ruiz Y, Seflaff T, Kepl L, Lake D. Analysis of human plasma peptide reveals potential biomarker for pancreatic cancer. J Proteome Res 2009, 8:4722-4731.
5. Katchman BA, Antwi K, Hostetter G, Mairet-Coello G, Tury A, Esnard-Feve A, Fellmann D, Miller LJ, Von Hoff DD, Lake DF. Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases. Mol Cancer Res 2011, 9:1621-1631.
6. Alon A, Heckler EI, Thorpe C, Fass D. QSOX contains a pseudo-dimer of functional and degenerate sulfhydryl oxidase domains. FEBS Lett 2010, 584:1521-1525.
7. Coppock DL, Thorpe C. Multidomain flavin-dependent sulfhydryl oxidases. Antioxid Redox Signal 2006, 8:300-311.
8. Heckler EI, Alon A, Fass D, Thorpe C. Human quiescin-sulfhydryl oxidase, QSOX1: probing internal redox steps by mutagenesis. Biochemistry 2008, 47:4955-4963.
9. Chakravarti S, Jessop CE, Miller M, Stirling CJ, Bullerd NJ. Intracellular catalysis of disulfide bond formation by the human sulfhydryl oxidase, QSOX1. Biochem J 2007, 404:403-411.
10. Maret-Coello G, Tury A, Ennard-Feve A, Fellmann D, Ristol PY, Griffond B. FAD-linked sulfhydryl oxidase QSOX: topographic, cellular, and subcellular immunolocalization in adult rat central nervous system. J Comp Neurol 2004, 473:334-363.
11. Tury A, Maret-Coello G, Poncelet F, Jacquemard C, Ristol PY, Fellmann D, Griffond B. QSOX sulfhydryl oxidase in rat adenohypophysis: localization and regulation by estrogen. J Endocrinol 2004, 183:353-363.
12. Coppock DL, Cina-Poppe D, Gilleran S. The quiescin Q6 gene (QSCN6) is a fusion of two ancient gene families: thioredoxin and ERV1. Genomics 1998, 54:460-468.
13. Alon A, Grossman I, Gat Y, Kodal Y, Delmao F, Mihelman T, Haran G, Baker D, Thorpe C, Fass D. The dynamic disulfide relay of quiescin sulfhydryl oxidase. Nature. 2012, 488:414-418.
14. Thorpe C, Hoober KL, Raje S, Burns M, Nightingale T, Turi GK, Coppock DL. Sulfhydryl oxidases: emerging catalysts of protein disulfide bond formation in eukaryotes. Arch Biochem Biophys 2002, 405:1-12.
15. Song H, Zhang B, Watson MA, Humphrey PA, Lim H, Milbrandt J. Loss of NixA1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 2009, 28:3307-3319.
16. Sarlje T, Penu CM, Tishinari R, Aas T, Geider S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matske JC, Brown PO, Botstein D, Lanning PE, Barresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
17. Ringner M, Fredlund E, Hakkinen J, Borg A, Staal J. GOBO: gene expression-based outcome for breast cancer online. PLoS One 2011, 6:e17911.
18. Perou CM, Sarlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lanning PE, Barresen-Dale AL, Brown PO, Botstein D. Molecular portraits of breast tumours. Nature 2000, 406:747-752.
19. Soule HD, Maloney TM, Wolman SR, Peterson WO, Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990, 50:6087-6094.
20. Tait L, Soule HD, Russo J. Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990, 50:6087-6094.
21. Motel C, Adami P, Musard JF, Duval D, Radom J, Jouvenot M. Involvement of sulfhydryl oxidase QSOX1 in the protection of cells against oxidative stress-induced apoptosis. Exp Cell Res 2007, 313:3971-3982.
22. Platt J, Bucur O, Khorosavi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 2011, 3:279-296.
23. Klionsky DJ. The molecular machinery of autophagy and its role in physiology and disease. Semin Cell Dev Biol 2010, 21:663.
24. Radosky ES, Radosky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:201-212.
25. Kohnmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 2009, 9:188.
26. Khoo BY, Miswan N, Balaram P, Nadarajan K, Elstner E. Modification of MCF-10A Cells with Pioglitazone and Serum-Rich Growth Medium Increases Soluble Factors in the Conditioned Medium, Likely Reducing BT-474 Cell Growth. Int J Mol Sci 2012, 13:5601-5627.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
28. Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011, 121:3786-3788.
29. Rziki A, Weaver VM, Lee SY, Rozenblig G, Chin K, Myers CA, Bascom JL, Mott JD, Semenits Jr, Grate LR, Mian IS, Borowsky AD, Jensen RA, Idowu MO, Chen F, Chin DJ, Petersen OW, Gray JW, Bissell MJ. A human breast cell model of preinvasive to invasive transition. Cancer Res 2008, 68:1378-1387.
30. Hu M, Polyak K. Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer 2008, 44:2760-2765.
31. Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila) 2010, 3:1361-1364.
32. Bacac M, Stamenkovic I. Metastatic cancer cell. Annu Rev Pathol 2008, 3:221-247.
33. Martin JK, Patrick DR, Bissell MJ. Fournier MV. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One 2008, 3:e2094.
34. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
35. Baovios B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012, 1825:29-36.
36. Jin Q, Yuan LX, Boulbes D, Berck JM, Wang YN, Gomez-Cabello D, Hwke DH, Yeung SC, Lee MH, Hortobagyi GN, Hung MC, Esteva FJ. Acaidynase phosphatidylcholine: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res 2010, 12:R86.
37. Portes KF, Ikegami CM, Getz J, Martins AP, de Noronha L, Zischler LF, Klassen G, Camargo AA, Zanata SM, Bevilacqua E, Nakao LS. Tissue distribution of quiescin Q6/sulfhydryl oxidase (QSOX) in developing mouse. J Mol Histol 2008, 39:217-225.

DOI:10.1186/bcr3407

Cite this article as: Katchman et al.: Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminar B breast cancer. Breast Cancer Research 2013 15:R28.